Governor’s Chair in Nuclear Medicine: Radiopharmaceutical Therapies

Governor’s Chair in Nuclear Medicine:
Radiopharmaceutical Therapies

Location: Knoxville, TN / Oak Ridge, TN

Open Date: Jul 10, 2025

The University of Tennessee (UT) Oak Ridge Innovation Institute (UT-ORII) invites applications for the position of Governor’s Chair in Nuclear Medicine with a focus on precision radiopharmaceutical theranostics (RPT). Strong candidates will have track records of distinguished contributions to advancing radiopharmaceutical development through new approaches to: a) the production of medically relevant radionuclides to image, and treat cancer and other diseases;

b) the design of novel chelators and nanocarriers to attach and retain radionuclides for targeted delivery to cancer cells; c) the development of novel targeting agents to detect cancer and metastatic disease; d) the development and use of theranostics for combination imaging and treatment modalities; e) radiation dosimetry, optimizing radiation dose treatment and delivery, including with the use of computational and artificial intelligence tools;

or f) combination therapies.

The successful Governor’s Chair in Nuclear Medicine will have an international reputation and demonstrated excellence in research and education, and will have a record of developing and leading multidisciplinary, translational programs and teams.

The GC will lead high‑profile research and work collaboratively with a growing network of radioisotope and radio chemists, including through the UT-ORII convergent research initiative titled “Development and Advancement of Radiopharmaceutical Therapies (DART)”. The successful candidate is expected to contribute to the DART initiative leadership, which includes supporting the recruitment and professional growth of ten new research faculty hires at UT and nine new research scientist hires  addition to advancing science‑ and technology‑based solutions for RPT leading to the more effective diagnosis and treatment of cancer and other debilitating disease, the DART initiative also aims to engage up to 100 graduate student researchers over five years to prepare future generations of RPT scientists and practitioners.

• Strategic Leadership: Lead the collaborative development of RPT programs at UT, UTMC and ORNL to advance nuclear medicine and radiopharmaceuticals and oversee critical activities such as staffing, student recruitment, and stakeholder relationship management.
• Academic Quality: Pursue leading research and support ongoing efforts to create an environment of simultaneous excellence in research, innovation, translation, education, and workforce development.
• Collaborations: Expand collaborations between UT, UTMC, ORNL and other regional, national and international partners.
• Funding: Leverage all relevant assets at UT, UTMC, and ORNL to lead the management of stakeholder relationships and capture significant extramural funds, building a sustainable portfolio of well‑funded activities in nuclear medicine.
• Community Relations: Support meaningful engagements with Tennessee communities and community organizations to amplify the translational impact of RPT in enhancing patient outcomes.
• Education: Develop new curricular offerings in the area of nuclear medicine and RPT and provide training for graduate students and postdoctoral researchers.

• PhD in Chemistry, Nuclear Engineering, Biomedical Engineering, Biochemistry & Cellular and Molecular Biology or closely related fields, or an MD or MD/PhD in Radiology, Radiation Oncology or Nuclear Medicine or closely related fields. Must be a tenured professor or senior researcher at a research institution, industry or national lab.
• Experience with clinical trials associated with diagnostic imaging, including PET/CT, SPECT, or radionuclide therapy is beneficial. Established record of research demonstrated through publications in peer‑reviewed journals, citation statistics, invited talks, leadership roles, and success in individual and extramural grants.
• Research strengths in one or more of the following areas:
  • Production of medically relevant radionuclides to image and/or treat cancer and other diseases.
  • Design of novel chelators and…